InflaRx NV (IFRX)
1.72
+0.01
(+0.58%)
USD |
NASDAQ |
Oct 02, 16:00
1.725
0.00 (0.00%)
After-Hours: 20:00
InflaRx Net Income (Quarterly) : -12.38M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -12.38M |
| March 31, 2026 | -6.543M |
| September 30, 2025 | -14.33M |
| June 30, 2025 | -16.34M |
| March 31, 2025 | -8.750M |
| September 30, 2024 | -19.17M |
| June 30, 2024 | -14.91M |
| March 31, 2024 | -10.48M |
| December 31, 2023 | -17.13M |
| September 30, 2023 | -8.106M |
| June 30, 2023 | -8.927M |
| March 31, 2023 | -11.89M |
| December 31, 2022 | -8.187M |
| September 30, 2022 | -7.975M |
| June 30, 2022 | 0.4953M |
| March 31, 2022 | -15.71M |
| December 31, 2021 | -14.48M |
| September 30, 2021 | -14.21M |
| June 30, 2021 | -17.82M |
| March 31, 2021 | -7.378M |
| Date | Value |
|---|---|
| December 31, 2020 | -10.56M |
| September 30, 2020 | -8.017M |
| June 30, 2020 | -11.05M |
| March 31, 2020 | -9.070M |
| December 31, 2019 | -15.11M |
| September 30, 2019 | -16.12M |
| June 30, 2019 | -17.16M |
| March 31, 2019 | -11.17M |
| December 31, 2018 | -11.73M |
| September 30, 2018 | -7.879M |
| June 30, 2018 | -2.909M |
| March 31, 2018 | -12.70M |
| December 31, 2017 | -13.78M |
| September 30, 2017 | -4.766M |
| June 30, 2017 | -5.146M |
| March 31, 2017 | -4.051M |
| December 31, 2016 | |
| September 30, 2016 | |
| June 30, 2016 | -1.205M |
| March 31, 2016 | -1.494M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| MediGene AG | -- |
| BioNTech SE | -954.35M |
| Immatics NV | -72.66M |
| Arrowhead Pharmaceuticals, Inc. | -178.92M |
| Oncolytics Biotech, Inc. | -9.442M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 12.38M |
| EPS Diluted (Quarterly) | -0.1052 |
| Enterprise Value | 73.20M |
| Earnings Yield | -37.70% |
| Normalized Earnings Yield | -33.01 |